IFP Advisors’s Starling Oncology STLN Stock Holding History

IFP Advisors’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71K	Hold	500	–	–	﹤0.01%	4093
2026 Q1	$1.53K	Hold	500	–	–	﹤0.01%	4058
2025 Q4	$1.78K	Hold	500	–	–	﹤0.01%	3880
2025 Q3	$1.75K	Buy	+500	New	+$1.71K	﹤0.01%	3755

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

IFP Advisors's STLN Position: Q2 2026 in Review

IFP Advisors held its Starling Oncology (STLN) position steady in Q2 2026 at 500 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #4093.

IFP Advisors first reported a position in STLN in Q3 2025 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

IFP Advisors held 500 shares of Starling Oncology worth $2.71K as of Q2 2026.
IFP Advisors left its Starling Oncology share count unchanged in Q2 2026.
Starling Oncology made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4093 holding.
IFP Advisors first reported a position in Starling Oncology in Q3 2025 and has held it in 4 quarters since.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.